PFS

Leah SherwoodTransplantation & Cellular Therapy | November 14, 2022
In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ...
Leah SherwoodAggressive B-Cell Lymphoma | November 14, 2022
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting.
Advertisement
Kerri FitzgeraldChronic Lymphocytic Leukemia | February 1, 2023
Updated findings from the ASCEND study were presented at the 2022 ASCO Annual Meeting.
Ariel DeMaioMyeloma | November 14, 2022
Findings support the use of MRD negativity as a prognostic tool to measure deep response, leading to improved PFS.
Advertisement
Advertisement
Advertisement